Why Tandem Diabetes Care, Inc.’s (TNDM) Stock Is Up 9.31%
As of Friday, August 07, Tandem Diabetes Care, Inc.’s TNDM share price has surged by 9.31%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Stock Evaluator: Tandem Diabetes Care, Inc. (TNDM)
Tandem Diabetes Care, Inc. TNDM
$22.32
-0.25
-1.11%
August 21, 2026 4:00:00 PM
EST
Volume: 1,636,304
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It’s flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Commentary & Analysis
Why Tandem Diabetes Care, Inc.’s (TNDM) Stock Is Up 15.91%
As of Friday, August 07, Tandem Diabetes Care, Inc.’s TNDM share price has surged by 15.91%, which has investors questioning if this is right time to sell.Tudor Pop
Why Tandem Diabetes Care, Inc.’s (TNDM) Stock Is Up 7.36%
As of Thursday, July 16, Tandem Diabetes Care, Inc.’s TNDM share price has surged by 7.36%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Tandem Diabetes Care, Inc.’s (TNDM) Stock Is Up 6.39%
As of Monday, July 13, Tandem Diabetes Care, Inc.’s TNDM share price has surged by 6.39%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Tandem Diabetes Care, Inc.’s (TNDM) Stock Is Up 5.73%
As of Thursday, June 25, Tandem Diabetes Care, Inc.’s TNDM share price has surged by 5.73%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | TNDM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,570.4 | $407.7 | 50% |
|
| Shares Out (Mil) | 69.0 | 41.3 | 55% |
|
| Institutional Ownership | 98.8% | 81.4% | 82% |
|
| Float (Mil) | 63.6 | 34.9 | 52% |
|
| Beta | na | 0.88 | na |
|
| Avg Daily Volume (000s) | 2,180 | 412 | 83% |
|
| Price Change (52-week) |
107.3% | 64.8% | 92% |
|
| Growth | TNDM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 15.3% | 11.8% | 74% |
|
| Net Income (5yr) | (42.9%) | (6.0%) | 9% |
|
| EPS (5yr) | (40.1%) | 10.4% | 5 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (14.7%) | (16.2%) | 55% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 18 | 19 | 19 | |
| Current EPS | ($0.241) | ($0.666) | $0.175 | |
| Month Ago EPS | ($0.189) | ($0.692) | $0.114 | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.187) | ($0.700) | $0.053 | |
| Year/Year Chg | (21.5%) | (78.1%) | (128.4%) | |
| Financials | TNDM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,041 | $119 | 51% |
|
| Net Income (TTM) (Mil) | ($63) | ($9) | 14% |
|
| EPS (TTM) | ($0.927) | ($0.400) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($6) | ($3) | 24% |
|
| Net Cash Flow (TTM) (Mil) | ($1) | $1 | 39% |
|
| Long-Term Debt (Q1) (Mil) | $719 | $21 | 62% |
|
| Enterprise Value (Q1) (Mil) | na | $427 | na |
|
| Valuation | TNDM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 12.01 | 3.06 | 92% |
|
| P/E | na | 27.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.7 | na |
|
| Ratios | TNDM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 56.0% | 58.9% | 68% |
|
| Net Margin | (6.1%) | (6.9%) | 24% |
|
| ROA | (6.2%) | (12.7%) | 28% |
|
| ROE | (48.0%) | (13.1%) | 16% |
|
| Liabilities to Assets | 88.7% | 46.0% | 83% |
|
| F-Score | 4 | 4 | 34% |
|
Passing Stock Screens
As of 8/20/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Kirkpatrick Bargain Screen
Factors: Value, Momentum
Investing model outlined in Charles Kirkpatrick's book, Beat the Market: Invest by Knowing What Stocks to Buy and What Stocks to Sell.
| Performance Since Inception: | 6.8% |
| +/- S&P 500: | -0.7 |
GURU STRATEGY
Lakonishok Screen
Factors: Value, Momentum
Identifying stocks trading at a discount to their industry norms but showing recent price strength and upward earnings revisions.
| Performance Since Inception: | 13.2% |
| +/- S&P 500: | +5.7 |
GURU STRATEGY
O'Shaughnessy: Growth Screen II
Factors: Value, Momentum
O'Shaughnessy tries to predict the future using historical long-term trends.
| Performance Since Inception: | 15.1% |
| +/- S&P 500: | +7.6 |
GURU STRATEGY
O'Shaughnessy: Small Cap Growth & Value Screen
Factors: Value, Size, Momentum
O'Shaughnessy tries to predict the future using historical long-term trends.
| Performance Since Inception: | 17.3% |
| +/- S&P 500: | +9.8 |
